Application of the Latest Immuno-Oncology Developments to the Treatment of Urothelial Cancer

Agenda

Events

Date / Time
Event Details

Faculty

This educational activity is not certified for CME/CE credit

Goal Statement
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use of the current and evolving immuno-oncology–based standard of care, first-line treatments, and sequencing in the care of their patients with urothelial cancer.

Target Audience
This targeted program is designed to both inspire and instruct urologists, medical oncologists, and other healthcare providers caring for patients with urothelial cancer (UC) around the world and especially in Europe (Big 5 EU and Switzerland) and South America (Argentina). The identified target audience will benefit from this education by gaining the knowledge necessary to integrate the use of immune checkpoint inhibitors (ICI) into the treatment of advanced UC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, taking into consideration the available evidence and patient and disease characteristics
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Discuss ongoing clinical trials investigating targeted systemic therapies and immune checkpoint inhibitor–based combinations for patients across the urothelial carcinoma disease spectrum
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors

Accreditation

This educational activity is not certified for CME/CE credit.